Canada on Thursday approved the use of Covifenz, the world’s first plant-derived Covid-19 vaccine jointly developed by Medicago Inc. and GlaxoSmithKline Plc. The vaccine has been cleared for people aged 18 to 64 since its safety and effectiveness, according to Health Canada, have not been established in people younger than 18 or older than 64 years of age.
The decision to authorize the vaccine was based on a study conducted on 24,000 adults that showed the efficacy rate of the vaccine is 71% at preventing COVID-19 – although the tests were conducted before the omicron variant emerged. Covifenz is the name given to this vaccine. Canada agreed to buy 20 million doses of this plant-based vaccine, with an option to purchase 56 million additional doses.
Medicago, the Quebec-based pharmaceutical company behind the plant-based jab, has agreed to supply the Canadian government with 76 million doses of the vaccine as soon as possible, the Associated Press reports.
